We've now entered the fourth decade of the AIDS epidemic, and according to The Joint United Nations Commission on HIV/AIDS (UNAIDS), the world has turned the corner. Since the epidemic peaked in 1999, the number of new infections has fallen by 19 percent. And, of the estimated 15 million people living with HIV in low- and middle income countries, 6.6 million have access to treatment.
Despite the positive trend overall, there is more work to be done. For example, while the rate of new HIV infections has declined globally, in some countries in Eastern Europe and Central Asia there are signs that new HIV infections are on the rise.
For nearly 25 years, Merck has sought to make a difference in the fight against HIV/AIDS through research, access programs and global partnerships. We are committed to the long-term battle against this disease.
Our commitment means that we are applying our scientific, operational and technological expertise to deliver healthcare solutions to help the millions of people worldwide who are living with HIV/AIDS.
As part of Merck's commitment to Corporate Responsibility, we support a variety of programs around the world.
See how Merck is helping:
Merck recently announced a partnership with the CALIBER (Clinic Activation to Lead and Implement Best practices for Enhancing Response to HIV) of Care® initiative. This partnership is designed to help improve HIV patient care by giving physicians educational resources to help strengthen physician-patient dialogue and address issues that represent barriers to care. The first resource available through the program is the Stigma Dialogue Navigator, which is designed to help address the stigma of HIV and empower patients to overcome its negative effect.